The Prospective Segeberg Registry for Coronary Chronic Total Occlusions (CTO)
Launched by SEGEBERGER KLINIKEN GMBH · May 2, 2025
Trial Information
Current as of September 30, 2025
Recruiting
Keywords
ClinConnect Summary
The Prospective Segeberg Registry for Coronary Chronic Total Occlusions (CTO) is a clinical trial that aims to study patients who have a specific heart condition called coronary chronic total occlusions. This condition occurs when a coronary artery is completely blocked, which can lead to heart problems. The trial is currently recruiting participants who are undergoing a procedure called recanalization, where doctors try to open up these blocked arteries using a minimally invasive technique.
To be eligible for this trial, participants need to be between the ages of 65 and 74 and must be scheduled for this recanalization procedure. There are no other exclusion criteria, meaning that if you meet the age requirement and have the condition, you can participate. If you join the study, you will be part of a follow-up assessment to help researchers understand the outcomes and effectiveness of the treatment over time. This could provide valuable information that might improve care for others with similar heart conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with coronary chronic total occlusions undergoing recanalization via percutaneous coronary interventions
- Exclusion Criteria:
- • None
About Segeberger Kliniken Gmbh
Segeberger Kliniken GmbH is a leading healthcare organization specializing in innovative clinical research and patient care. With a commitment to advancing medical science, the company conducts a range of clinical trials aimed at developing new therapies and improving treatment outcomes across various medical disciplines. Backed by a team of experienced professionals and state-of-the-art facilities, Segeberger Kliniken GmbH collaborates with academic institutions and industry partners to ensure the highest standards of clinical excellence and ethical practices. Their dedication to patient safety and scientific integrity positions them as a trusted sponsor in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bad Segeberg, Schleswig Holstein, Germany
Patients applied
Trial Officials
Holger Nef, Prof., MD
Study Director
Herzzentrum Segeberger Kliniken GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported